Kailera Therapeutics Appoints Kathleen Tregoning as Chief Corporate Affairs Officer
Company expands executive team with strategic corporate affairs leader as it advances its differentiated obesity portfolio
WALTHAM, Mass., June 29, 2026 (GLOBE NEWSWIRE) -- Kailera Therapeutics, Inc., a clinical-stage biotechnology company focused on elevating the next era of obesity care, today announced the appointment of Kathleen Tregoning as Chief Corporate Affairs Officer.
“We are delighted to welcome Kathleen to our leadership team as we advance our late-stage clinical trials in obesity and navigate the rapidly evolving obesity treatment landscape,” said Ron Renaud, President and Chief Executive Officer of Kailera. “Kathleen is a seasoned executive with deep experience helping biopharmaceutical companies build trust, navigate complexity, and engage stakeholders around a shared mission. Her strategic perspective will be invaluable as we advance our mission to deliver new options to people living with obesity.”
“Obesity is one of the most significant healthcare challenges facing society today, and continued innovation will be essential to meeting the needs of patients, providers, and healthcare systems,” said Kathleen Tregoning, Chief Corporate Affairs Officer of Kailera. “Kailera is building a differentiated portfolio designed to expand treatment options in this dynamic field. I am excited to join the company at this important stage of growth and look forward to fostering engagement with stakeholders, supporting a policy environment that enables continued innovation, and helping build understanding of Kailera’s vision, science, and progress among the communities we serve.”
Kathleen brings more than two decades of experience leading global corporate affairs organizations and guiding innovative biopharmaceutical companies through complex policy, regulatory, reputational, and stakeholder environments.
Kathleen previously served as Chief Corporate Affairs Officer and Head of Commercial Strategy at Cerevel Therapeutics, where she helped lead the neuroscience company through a period of significant growth prior to its acquisition by AbbVie in 2024. Prior to joining Cerevel, she was Executive Vice President, External Affairs at Sanofi, where she led a global organization responsible for developing external engagement strategies, shaping healthcare policy, and advancing access to innovative therapies. She spent more than a decade at Biogen in positions of increasing responsibility, ultimately serving as Senior Vice President, Corporate Affairs, where she led communications, patient advocacy, public policy, and government affairs activities across the company's global business. Earlier in her career, she was a professional staff member in health policy for multiple committees of the United States Congress.
Kathleen graduated from Stanford University with a degree in International Relations and holds a graduate degree in Public Policy from the Harvard Kennedy School. She currently serves as an independent director on the boards of Compass Pathways (Nasdaq: CMPS) and Spero Therapeutics (Nasdaq: SPRO).
About Kailera Therapeutics
Kailera Therapeutics (Kailera) is a clinical-stage biotechnology company focused on elevating the next era of obesity care by progressing a diversified pipeline to provide options for people living with obesity no matter where they are in their treatment journey. With an obesity-first focus, Kailera is advancing four clinical-stage product candidates leveraging multiple GLP-1-based mechanisms of action and routes of administration specifically designed to address critical needs in the current therapeutic landscape with a lead product candidate, ribupatide injection (also known as KAI-9531), that has the potential for the greatest weight loss. Ribupatide injection is in global Phase 3 trials as a once-weekly injectable GLP-1/GIP receptor dual agonist. Kailera is expanding the ribupatide franchise by developing a once-daily oral formulation with the goal of providing an oral option with the potential for compelling weight loss and highly differentiated tolerability. Additionally, Kailera is advancing the development of KAI-7535, a once-daily oral small molecule GLP-1 receptor agonist, and KAI-4729, a once-weekly injectable GLP-1/GIP/glucagon receptor tri-agonist. Kailera’s vision is to deliver category-leading obesity management medications that give people the power to restore their health and transform their lives. Kailera is based in Waltham, MA. For more information, visit www.kailera.com and follow us on LinkedIn and X.
Special Note Regarding Kailera Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the profile of product candidates, the potential of Kailera’s portfolio, the timing, design and outcome of research and development activities, market opportunities for product candidates, and the competitive landscape. Forward-looking statements can be identified by terms such as "anticipate," "believe," "contemplate," "continue," "could," "estimate," "expect," "intend," "may," “suggest,” "plan," “goal,” “vision,” "potential," "predict," "project," "should," "target," "will," "would," or similar expressions and the negatives of those terms. Kailera cannot assure you that the forward-looking statements in this press release will prove to be accurate. Information in this press release may also include statements relating to past performance, which should not be regarded as a reliable indicator of future performance. Forward-looking statements are based on current expectations and assumptions together with projections of the future which are inherently uncertain, and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks and uncertainties include, among others, uncertainties inherent in clinical development, regulatory review, manufacturing, competition, market opportunities, reliance on third parties, estimates of capital requirements, needs for additional financing, and other important factors, including those discussed under the caption “Risk Factors” in Kailera’s filings with the Securities and Exchange Commission. These statements speak only as of the date of this press release, and Kailera undertakes no obligation to update or revise any forward-looking statements. Kailera may not actually achieve the plans, intentions, or expectations disclosed in its forward-looking statements, and you should not place undue reliance on these forward-looking statements.
Contact Information:
Media
media@kailera.com
Investors
Maura Gavaghan
Vice President, Investor Relations
maura.gavaghan@kailera.com
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
